Real-Time Post-Apheresis Documentation Decreases Errors
Publication
Article
BioPharm InternationalBioPharm International, Emerging Therapies September 2022
Volume 2022 eBook
Issue 3
Pages: 14–16
Document integrity is critical in the provision of raw materials for cell and gene therapy manufacturing.
greenbutterfly/Stock.adobe.com
There is a need for more universally accepted definitions and processes involving chain of identity and chain of custody documentation for raw materials used in cell and gene therapies. Although current good documentation practices exist and are enforced by regulatory bodies, there is a vast discrepancy in how these practices are implemented across the industry. The industry must take steps to improve documentation integrity and standardize to reduce risk. Until standardization occurs, it will be difficult to ensure a system for raw material documentation.
Read this article in BioPharm International’s September 2022 Emerging Therapies 2022 eBook.
About the author
Julie Tilbury is a collection network liaison at Be The Match BioTherapies.
Article Details
BioPharm International
eBook: Emerging Therapies 2022, September 2022
September 2022
Pages: 14–16
Citation
When referring to this article, please cite it as J. Tilbury, “Real-Time Post-Apheresis Documentation Decreases Errors," BioPharm International Emerging Therapies 2022 eBook (September 2022).
Articles in this issue
Treating Cancer with Oncolytic Viruses
Accelerating the Development of mRNA Therapeutics
Real-Time Post-Apheresis Documentation Decreases Errors
Shining a Light on Lipid Nanoparticle Characterization
The Road to Personalized Medicine: Reimagining Drug Manufacturing
Novel Therapies of 2022
Biotech Incubators Cultivate a Global Scene
Recent Videos
